Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + SBRT +/- UDCA in HER2- Breast Cancer
NCT06842472Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of ursodeoxycholic acid in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06842472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842472.